EUR/USD 1.14254
0.080%
Gold 4073.83
-0.088%
Oil 73.879
-0.855%
USD/JPY 162.440
-0.093%
GBP/USD 1.33957
0.052%
GBP/JPY 217.606
-0.034%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
N Yonglis stock price initially surged by over 100%, but the increase has since fallen back to 87.5%.Qiyunshan Food (02797.HK) surged over 120% on its first day of trading, currently trading at HK$17.67 per share, compared to its issue price of HK$8 per share.On July 9th, Dong Lijuan, Chief Statistician of the Urban Division of the National Bureau of Statistics, interpreted the CPI and PPI data for June 2026. On a month-on-month basis, the national CPI decreased by 0.3%. Affected by fluctuations in international market prices, domestic gold jewelry and gasoline prices decreased by 8.7% and 4.9% respectively, with the declines widening by 5.9 and 4.6 percentage points respectively compared to the previous month. These combined contributed to a month-on-month decrease of approximately 0.22 percentage points in the CPI, an increase of approximately 0.19 percentage points in their downward pull on the CPI compared to the previous month. Food prices decreased by 0.4%, the same decline as the previous month, contributing to a month-on-month decrease of approximately 0.07 percentage points in the CPI. In the food sector, abundant seasonal fruits and vegetables led to ample market supply, resulting in a 1.0% and 2.0% decrease in fresh vegetable and fruit prices, respectively, contributing to a combined month-on-month decrease in CPI of approximately 0.06 percentage points. Pork and aquatic product prices decreased by 0.8% and 0.6%, respectively, contributing to a combined month-on-month decrease in CPI of approximately 0.02 percentage points. Meanwhile, low laying hen inventory, coupled with a decline in egg production due to high temperatures, led to a 7.0% increase in egg prices, contributing to a month-on-month increase in CPI of approximately 0.03 percentage points.Zhipu (02513.HK) rose more than 10% as the company plans to raise over HK$31.4 billion through a share placement at a discount of approximately 13%.On Thursday, July 9, the Hang Seng Index opened down 18.12 points, or 0.07%, at 24,181.34; the Hang Seng Tech Index opened up 13.95 points, or 0.29%, at 4,744.97; the H-share Index opened up 0.27 points, or 0.0%, at 8,083.95; and the Red Chip Index opened down 9.41 points, or 0.24%, at 3,865.52.

AstraZeneca's nasal spray vaccine trial for COVID experiences a setback

Charlie Brooks

Oct 11, 2022 11:23

16.png


Tuesday, attempts by researchers from Oxford University and AstraZeneca (NASDAQ:AZN) Plc to manufacture a nasal-spray version of their jointly developed COVID-19 injection were hindered by the failure of first human tests to give the required degree of protection.


During the first of generally three phases of clinical testing, a minority of trial participants had an antibody response in their respiratory mucous membranes, according to a statement released by the University of Oxford on Tuesday.


In addition, the immune response measured in the blood was weaker than that caused by an arm injection.


Researchers from throughout the world have high hopes for nasal spray vaccinations against the coronavirus, as it is predicted that the method could prevent infection and illness by stimulating an immune response directly in the airways, where the virus enters the body.


In addition, the method would be less painful and easier to administer than injections.


In India and China, regulators have previously authorized the administration of drugs via the airways.


Last month, India's health minister approved Bharat Biotech's COVID-19 nasal spray vaccine, while China's medicines regulator approved CanSino Biologics Inc's COVID-19 inhaled vaccine on an emergency basis.


CanSino has said that its nebuliser-delivered vaccine can develop robust immunity to successfully restrict disease, but Bharat's trial findings are not yet available.


The British study included 30 unvaccinated patients and 12 volunteers who had previously undergone a normal two-dose immunization course.


In this study, the nasal spray did not perform as well as anticipated, according to Sandy Douglas, the trial's primary investigator at the Jenner Institute of Oxford University.


She went on to say, "We believe that delivery of vaccinations through the nose and lungs remains a viable option, but this study suggests that there will be challenges in making nasal sprays a reliable alternative."


During the AstraZeneca-funded trial, no severe adverse events or safety concerns were reported, according to the release.

Suggestion